could reach $4.5 billion annually and said the drug likely won’t go to market before 2020.
In addition to sharing the clinical data, Arrowhead announced a new candidate, ARC-251, designed to complement ARC-520. ARC-521 targets covalently closed circular DNA (cccDNA), a special DNA structure that appears and can stay in a cell nucleus as a virus spreads. Indicators point to cccDNA producing greater amounts of S-antigen in patients who are E-antigen-negative than in E-antigen-positive ones. The company says ARC-521 has been validated in chimps and it expects to file paperwork with the FDA for a new drug designation by mid-2016.
Arrowhead is based in Pasadena, CA. Its R&D operations are headquartered in Madison, WI.
